Sign in
Active, not recruitingPhase 2

Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome

Key facts

Who runs it
University of Arizona
Where
Tucson, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
36 people, planned
Started
29 Sept 2023
Ended
Jun 2026
Type of study
Interventional
Treatments tested
  • Atomoxetine and Oxybutynin (ato-oxy)
Record updated
7 April 2026

Who can take part

Age
6 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Male or female participants between 6 to 17 years of age, inclusive, at the Screening Visit
  • Known diagnosis of Down syndrome (trisomy 21, but not translocation or mosaicism)

Who cannot take part

  • Currently using and adherent to positive airway pressure therapy (>4 hours per night for 70% of nights in the past 30 days based on device download or parent report)
  • Monoamine oxidase inhibitor use
  • Seizure disorder
  • Congenital heart disease and not cleared to participate by the patient's cardiologist
  • History of current, untreated depression
  • History of liver disease
  • Prematurity < 32 weeks estimated gestational age
  • Presence of central sleep apnea on polysomnography (central AHI ≥ 5)
  • Urinary retention
  • Untreated or inadequately treated hypothyroidism
  • Significant traumatic brain injury
  • 3+ or greater tonsillar hypertrophy
  • Positive urine pregnancy test
  • Hypoxemia independent of respiratory events on baseline polysomnography (≥5 minutes with oxygen saturation <90%)
  • Presence of central sleep apnea on baseline polysomnography (central AHI ≥ 5)
  • Absence of OSA defined as total AHI <5 on baseline polysomnography

Where in United States

  • University of ArizonaTucson, United States

About the trial

What the trial wants to find out

This is an open-label study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with Down syndrome and obstructive sleep apnea (OSA) documented by polysomnography (PSG). Participants will receive ato-oxy for 6 months. Ato-oxy dose will be 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine. Dosing of the study treatment will occur approximately 30 minutes prior to bedtime. Participants who withdraw from the study will not be replaced.

Read full original descriptionShow less

Study participants will undergo eligibility screening that will include an initial screening to determine whether non- PSG enrollment criteria are met, followed by a 1 night in-lab PSG and health-related quality of life (HRQOL) and cognitive assessment for participants who qualify based on non-PSG criteria. For participants who are eligible and enroll in the study, the screening PSG night will serve as the baseline measure for apnea hypopnea index (AHI) and other PSG endpoints. On the final night of dosing for ato-oxy participants will return for inpatient PSG and health-related quality of life assessment and cognitive assessment. The primary efficacy endpoint is the change in obstructive AHI from baseline.

The group in the trial

  • Ato-oxyTreatment being tested

    0.5 mg/kg (max 40 mg) atomoxetine and 5 mg oxybutynin

    Treatment: Atomoxetine and Oxybutynin (ato-oxy)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
7 April 2026